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The effects of gold nanoparticles in 125I brachytherapy dose enhancement on choroidal Melanoma are 
examined using the Monte Carlo simulation technique. Usually, Monte Carlo ophthalmic brachytherapy 
dosimetry is performed in a water phantom. However, here, the compositions of human eye have been 
considered instead of water. Both human eye and water phantoms have been simulated with MCNP5 
code. These simulations were performed for a fully-loaded 16 mm COMS eye plaque containing 13 125I 
seeds. The dose delivered to the tumor and healthy tissues have been calculated in both phantoms, with 
and without GNPs. The results indicates that the dose to the tumor in an eye-ball implanted with COMS 
plaque increases with increasing GNPs concentration inside the target. Therefore, the required irradiation 
time for the tumors in the eye is decreased by adding the GNPs prior to treatment. As a result, the dose to 
healthy tissues decreases when the irradiation time is reduced. Furthermore, a comparison between the 
simulated data in an eye phantom made of water and eye phantom made of human-eye composition, in 
the presence of GNPs shows the significance of utilizing the composition of eye in ophthalmic 
brachytherapy dosimetry. Normally, the radiation therapy of cancer patients is designed to deliver a 
required dose to the tumor while sparing the surrounding healthy tissues. The results demonstrated that 
the use of GNPs enable us to overcome this challenge. Also, defining the eye composition instead of 
water will leads to more accurate calculations of GNPs radiation effects in ophthalmic brachytherapy 
dosimetry.  
 
Keywords: Choroidal Melanoma, Brachytherapy, MCNP5, Gold nanoparticles, Dose 
enhancement 
*Corresponding Author: Somayeh Asadi, E-mail address: s_asadi@sina.kntu.ac.ir  
 
PACS numbers: 87.53.Jw, 87.85.Rs, 87.10.Rt 
2 
 
I. Introduction  
Ocular melanoma or more specifically, uveal melanoma is a malignant tumor which can 
arise from the melanin-producing cells or melanocytes residing within the uvea. These kinds of 
tumors have the highest rate of metastasis of any intraocular cancer. The method of treatment is 
determined according to the type of the cancer and the rate of its progress.1-3 Enucleation, local 
resection and radiation therapy are the most common methods of treatment for ocular 
melanoma4. In radiation therapy, penetrating radiation like X-ray, gamma-ray, alpha and beta 
beams are used. These radiation types could be emitted from either a radiation apparatus such as 
linear accelerator or sealed radioactive sources (also known as brachytherapy sources) or from 
radio-labeled substances. Brachytherapy is a form of radiation therapy which involves placing 
small sealed radioactive seeds inside or adjacent to the tumor.5-6 Studies have shown that for 
most eye melanomas, the methods of using removable ophthalmic plaques loaded with 
brachytherapy sources are as effective as surgery (Enucleation).7-9  
Several isotopes, including 125I and 103Pd are used in the brachytherapy of choroidal 
Melanoma.10-12 Increasing the dose to the tumor, while decreasing the dose to the normal tissues 
remains as one of the biggest challenges in radiation therapy. Therefore, the design of the 
ophthalmic plaques and selection of the radionuclide for intraocular cancers has been the primary 
goal of the clinical studies for many investigators.13-15 Several investigations based on Monte 
Carlo simulations or experimental techniques have been performed for dosimetry of choroidal 
Melanoma, using different ophthalmic plaques containing various brachytherapy sources7-10, 13.   
Presently, there is increased interest in the potential use of gold nanoparticles (GNPs) as a 
dose enhancer in resolving the noted challenges in the treatment cancer patients through 
ionization radiation.15-16 In the context of such a treatment modalities, GNPs are considered to 
have advantageous characteristics such as biocompatibility, inertness and no reported obvious 
toxicity17-18. High photon interaction cross section of gold resulting from its high atomic number 
and electron density increases the possibility of dose absorption by GNPs. Because of the strong 
photoelectric absorption and secondary electron released by low energy gamma-ray or X-ray 
irradiation, GNPs can increase in dose enhancement factor (DEF) which will accelerate DNA 
strand breaks.19-21 DEF is defined as the ratio of the absorbed dose by the tumor containing 
GNPs, to the absorbed dose by the tumor without these nanoparticles. In an in-vivo study in mice 
bearing subcutaneous EMT-6 mammary carcinoma, Hainfeld et al.22 demonstrated that the 
presence of GNPs in the tumor will cause more absorbed dose by the cancerous cells than that of 
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the healthy tissues. Irradiation stability and cytotoxicity of GNPs in human K562 cells have been 
investigated by Xiao-Dong Zhang et al16 and the results indicated that GNPs do not deteriorate 
under high energy ray irradiation and showed concentration-dependent cytotoxicity. Also, the 
toxicity of the nanoparticles have been examined via different ways of assessing the cell viability 
like methyl thiazol tetrazolium (MTT) and Cell Titre-Glo™ luminescent cell viability assay.16, 23  
In some of the In-Vivo and In-Vitro studies23-27, after intravenous injection of nanoparticles, 
transmission electron microscopy (TEM) demonstrated that GNPs are accumulated in clusters 
within the membrane bound vesicles and lysosomes. The tumor vasculature shows more 
transmission than the normal blood vessels and there is no lymphatic drainage in the tumor. So, 
due to the poorly formed tumor vasculature, the accumulation of unlabeled nanoparticles within 
the tumor can occur under passive targeting by increasing the effect of permeability and retention 
(EPR) 28-29.  Several other studies demonstrated the effects of GNPs in radiation treatment of the 
different tumors.23, 30-38 
In the Monte Carlo study by Lechman et al35, it is reported that the energy deposited by 
photoelectrons in the tumor area, is more important than the size and concentration of gold 
nanoparticles.  However, in an independent project by Leung et al 36 using the MC technique, it 
was shows that gold nanoparticles with larger diameter and concentration increases the DEF in 
the tumor area. This means that to attain more precise results and knowing the parameters 
effective in cancer treatment by gold nanoparticles, more studies and examinations should be 
carried out.  
Considerable advances have been made in the application of nanotechnology-based 
cancer therapy and numerous studies have been carried out in this field through Monte Carlo 
simulation and experimental studies. However, only limited studies have been reported that 
relate eye tumors. From these resources, Sheng Zhang et al39 has studied the particles 
accumulation in the uveal tissue. In this report, the combination of nanoparticles of a suitable 
size with the ligands specified for the uveal melanoma cells has been found to be a good way for 
transferring these particles to the tumor area which would help them to stay in the melanoma 
tissue for a long time. In addition, they have reported that nanoparticles can escape through the 
uveal into the melanoma tissue with much higher accumulation than the micro-particles with 
optimal sizes of 100 nm to 300 nm. In a different study, Shin J. Kang et al40 have evaluated the 
efficacy of subconjunctival nanoparticles carboplatin in the Murine Retinoblastoma treatment.  
However, to our knowledge, the impact of the nanoparticles on the radiation dosimetry of the eye 
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has not yet been evaluated. Therefore, this project has been designed to evaluate the 
enhancement of the absorbed dose by the presence of the GNPs within the human eye 
considering both water and human eye compositions.    
In this study we have investigated the application of GNPs in brachytherapy on the eye 
tumor by Monte Carlo simulations. These simulations are performed with the eye model 
phantom and water phantom (eye model filled with water ) to determine the dose enhancement 
factor (DEF). In addition, the significance of the eye model on the DEF calculation has been 
evaluated by comparing the dosimetry calculations in the presence of GNPs in both eye model 
phantom and water phantom. These simulations are performed using MCNP5 Monte Carlo code. 
Dosimetric characteristics of a single source were utilized to validate the accuracy of the Monte 
Carlo simulation technique.  Also the dose distributions of the multi-source implant geometry in 
both eye and water phantoms with 16mm COMS standard eye-plaque loaded with 125I, model 
6711 source (manufactured by GE Healthcare/Oncura) have been simulated. 
 
II. Material and Method 
A. Monte Carlo Simulation  
In this project, the MCNP5 code41 has been utilized to evaluate the effect of GNPs on 
dose enhancement for treatment of ocular melanoma with 125I eye-plaque therapy. This code 
utilizes a three-dimensional heterogeneous geometry and transports for photons and electrons in 
the energy range from 1 KeV to 1 GeV. For the simulations of this project, the default MCNP5 
photon cross-section library, which is based upon release 8 of the ENDF/B-VI42 has been 
utilized. The simulations were performed with the *F8 tally for the phantom dosimetry and *F6 
tally for the air kerma simulations.  The calculated data in MeV per incident particle for each 
section of the phantom was then converted to absorbed dose (i.e. Gy) or absorbed dose rate per 
air kerma strength of the source (i.e. cGy h-1U−1) by introducing appropriate conversion factors 
following the published guidlines.43-44 Number of 7*107 and 2*109 histories have been followed 
to simulate the air kerma and phantom dosimetry, respectively, in order to achieve a relative 
statistical error of less than 1%. Table 1 shows the error propagation of the Monte Carlo 
simulation with MCNP5 in this project.                                     
The effects of the nanoparticles were calculated by performing the simulation in the eye-
model filled with the water and human eye composition, with and without the presence of the 
GNPs.  Moreover, the geometric design of a 16mm COMS standard eye-plaque, loaded with 13 
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125I, model 6711 source (manufactured by GE Healthcare/Oncura) have been introduced in the 
simulations. The water phantom and the human eye globe geometries (Figure 1) were designed 
in a manner similar to the one described in our previous work.45 
 
Figure 1: The longitudinal cross sectional diagram of the simulated human eye. In the left panel (a), the 
origin of the eye coordinate system is located at the center of the eye phantom. The voxels (numbered 1 to 
6) indicate the lens, sclera, Tumor apex, opposite side, Macula and optic nerve, respectively. In right 
panel (b), the origin of the plaque coordinate is at the interior surface of the sclera. The tally cells on this 
figure are shown along the central axis of the plaque, starting from sclera near the plaque to the sclera at 
the opposite side of the eye. 
 
 As has been emphasized in the previous report, the geometry and characteristic of this 
simulated eye globe have been determined in a manner that the dimension and specification of 
main parts of the human eye could be in conformity with the medical data44-53. The chemical 
compositions and densities of different components of the eyeball tissues which were used in 
these simulations are given in Table2. Due to the nervous complexity of the Retina and the 
vascular complexity of the choroid, their density and chemical compositions were assumed to be 
the same as water. A brief description of the components and shapes of the eyeball used in these 
simulations are given in the following section. 
The dimensions of the adult human eyeball are relatively constant and may vary by only 
one or two millimeters, from one person to another. Normally, an adult eyeball has an anterior to 
posterior diameter of 24 millimeters, but the vertical and horizontal diameters are approximately 
23mm and 23.5 mm, respectively. Therefore, a spherical shell of 24.6 mm has been considered 
as an eye globe, during these simulations. In these simulations, the common volume between 
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four concentric spheres with radii of 0.93, 1.03, 1.13 and 1.23 cm (centered at the center of the 
eye) are the introducer of Retina, Choroid and Sclera, (three primary layers of the eye), 
respectively. The Vitreous humor fills the space between the Lens and the smallest sphere (the 
inner surface of the Retina). The lens was defined as an ellipsoidal shape with equatorial 
diameters of 8mm and 9mm and a polar diameter of 0.25 cm.  Also, the optic nerve has been 
defined as the volume between two concentric cylinders with diameters of 7 mm and 8 mm, 
which was located at the outer layer of the Sclera. The skull bone has been simulated by 
considering the volume between two concentric spheres (centered at the origin of the eye 
coordinate) with radii of 1.505 cm and 2.05 cm. In both water and human eye globe phantom, the 
array of 0.5×0.5×0.5 mm3 voxels have been utilized for scoring the average energy deposition to 
different points in the eyeball (Figure1-B). We have examined that the use of smaller voxel size 
(i.e. 0.1×0.1×0.1 mm3) will lead to similar results but with much longer run time on computer, in 
order to achieve similar statistical uncertainties.  Therefore, this voxel size (i.e. 0.5×0.5×0.5 
mm3) utilized for the final data collection. These tally cells are selected along the central axis of 
the plaque, starting from sclera near the plaque to the sclera at the opposite side of the plaque.  
 
A single source dosimetry of Model 6711 125I source was used to validate the accuracy of 
the source and phantom geometry used in these Monte Carlo simulations. TG-4354-55 
recommended dosimetric characteristics of the single source (i.e. dose rate constant, radial dose 
function, and 2D anisotropy function) were compared with the published data for this validation 
process. These simulations were performed using a single source located at the center of a 
30×30×30 cm3 water phantom. To calculate the dose fall-off of the source, along its transverse 
axis with the smaller statistical fluctuations, toroid tally cells (torus-shaped cells) were selected.  
The major radii of these cells were chose to be in the range of 0.05 cm to 10 cm. The minor radii 
of the toroid cells, “R”, varied as a functional of radial distance as; [R=0.008 cm for 0.05 < r ≤ 
0.1; R=0.01 cm for 0.1 < r ≤ 1 cm; R=0.05 cm for 1 < r ≤ 5; and R=0.1 cm for 5 < r ≤ 10 cm].  
In the Monte Carlo calculations of this project, the simulations for air kerma rates are 
performed with the tally cells for scoring the collisional kerma at various distances relative to the 
source center. The calculated air kerma rates have been scored in the toroid cells filled with the 
dry air and located at distances ranging from 0.05 cm to 20 cm in vacuum and F6 tally was used. 
The air kerma strength is defined as the product of the air kerma rate at a given distance from the 
source center in vacuum by the square of the distance, as defined in the TG-43U1 
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recommendation. The SK is independent from the distance. The air kerma strength was then 
calculated for all the distances and has been found to be constant from 1cm to 10 cm with 
relative statistical uncertainties less than 0.1%, so the average value in this region has been taken 
as the air kerma strength per history. 
 
B. Choroidal Melanoma   
Choroidal Melanoma is one of the three kinds of the Uvea melanoma (choroidal, ciliary 
body and iris melanoma).  Treatment of the intraocular tumor depends on its basal diameter and 
apical height.  Plaque brachytherapy can be used for the treatment of tumors with the apical 
height of 2.5 to 10 mm and the basal diameter of 16 mm or less.  
In this work, a choroidal melanoma tumor with the apical height of 5 mm (i.e. 6mm from the 
exterior surface of the Sclera, according to COMS definition for the point of dose prescription56 
has been simulated in both phantoms. This tumor has been assumed to be on the lateral portion to 
the eyeball on the equator.  
 
C. Ophthalmic Plaque and Brachytherapy Source  
In these investigations, a fully-loaded 16 mm COMS eye plaque, containing 13 125I 
(model 6711, GE Healthcare/Oncura) brachytherapy sources have been modeled. These sources 
were sandwiched between a gold plaque with a density of 15.8 g/cm3 and Silastic seed-career 
with a density of 1.12 g/cm3. The geometric information and composition of the simulated 
plaque were obtained from some published references57-62.  Also, the coordinates of the13 seeds 
for this plaque are in accordance with the standard position for COMS-plaque56. Moreover, the 
detailed geometric and characteristic information of the model 6711 125I sources have been 
obtained from the publicly accessible website of the Carleton Laboratory for Radiotherapy 
physics seeds database63. The photon spectra quoted in TG-4354 has been used to sample the 
initial photon energies and probabilities for these brachytherapy sources. In these simulations, 
both water and human eyeball phantom with the fully loaded eye-plaque were placed in a 
30×30×30 cm3 water phantom, for the final dosimetric evaluations. The location of the eyeball in 
this phantom was selected such that it nearly represented the real patient anatomy (i.e., the 
cornea of the eye was toward one surface of the cubical phantom). 
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D. Gold Nanoparticles (GNPs) 
In our simulation, 50 nm GNPs were uniformly distributed within the tumor, in both eye 
phantoms filled with the water and the eye composition to create different concentrations (i.e. 
milligram of GNPs per gram of the target tissue) of 7, 10, 18 and 30 mg/g. From the simulated 
absorbed dose to different points of interests in the eyeball, with and without the presence of the 
GNPs, the values of the dose enhancement factors were calculated.  Considering a treatment time 
of 100 hours, a procedure introduced by Thomson et al44 was utilized to achieve a dose of 85 Gy 
at the tumor apex. 
 
III. Result  
A. Calculation of TG-43 Parameter (Single Source) 
The accuracy of the seed model used in this study has been benchmarked via calculations 
of the TG-43 dosimetry parameters (Air Kerma Strength, dose rate constant and radial dose 
function) and comparison with the published results reported by Taylor et al63 and M. J. Rivard 
et al54.   
Table 3 and Figure 2 shows excellent agreement (within ±5%) between the presently 
calculated radial dose function (RDF) of a single Oncoseed 125I (Model 6711) brachytherapy 
source and the reported data by Rivard et al54 and Taylor et al63. 
 
Figure 2: Radial dose function for 125I source. Voxel sizes are: 0.008 cm for distance between 0.05 < r ≤ 
0.1, 0.01 cm for 0.1 < r ≤ 1 cm, 0.05 cm for 1 < r ≤ 5 and 0.1 cm for 5 < r ≤ 10. Symbol of Circle and 
Triangle are values calculated by Taylor et al63 and J. Rivard et al54. 
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 Moreover, the dose rate at the reference point, (r0 = 1 cm, 𝜃0 = π/2) has been calculated, 
Ḋ (r0, 𝜃0), as the dose to water per photon history in a torus tally cells with 0.01cm minor cross 
sectional diameter. It should be noted that R0 and 𝜃0 are the transverse axis polar coordinates 
relative to the source center.  The dose rate constant, Ʌ, has been obtained as the ratio of the 
calculated dose rate to the air kerma strength (SK) with the unit of cGy.h
-1U-1. The symbol U is 
the unit of air-kerma strength of the source and it is defined as 1U=1 cGy.cm2.h-1. The result 
gained from this study and those reported by TG-4354 and Taylor et al63 are listed in Table 4.  
Figure 3 displays the isodose contours in the x, y plane at z=0 for a 16 mm COMS Plaque 
loaded with 13 125I Oncoseeds (Model 6711). This plaque has been simulated at the center of the 
water phantom and the dose has been scored in (0.1 cm)3 voxels. In this plot, the 100% line dose 
is located at the tumor apex. As the distance from this point increases, dose values decrease 
rapidly which is the main benefit of this treatment modality.  
 
Figure 3: Z-plane, 16 mm plaque (in water) isodose lines from MCNP, 100% at tumor apex. 
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B. Dosimetry calculations 
 
Figure 4 (a) shows the depth dose curve for 125I sources in a fully-loaded 16 mm COMS 
eye plaque in both water and eye phantoms (without the presence of the tumor), relative to the 
dose value at 5 mm depth (where in this work tumor apex is assumed to be). These results show 
an agreement between the two sets of data for all the points except the first and last points that 
falls on the sclera adjacent to the plaque and opposite to the plaque, respectively.  The dose value 
to the first and the end voxel in the eye phantom are approximately 26% higher than that of the 
voxels in water phantom. Based on the similarity between the elemental composition of the 
vitreous body and water, it is clear that the dose in the vitreous is approximately similar to that of 
the water. Moreover, the calculated depth dose in the water phantom has been compared with 
those calculated data by Thomson et al44 (Figure 4 (b)) with an excellent agreement (within the 
uncertainties shown in Table 1) between them.  
 
Figure 4: (a) The Plaque central axis depth-dose curves for I125 in the water and the eye phantom. (b) 
Comparison of the Plaque central axis depth-dose in the water phantom between this work and the work 
by Thomson et al44. The vertical axis represents the ratio of dose to the dose at the tumor apex. 
                      
Figure 4 shows the depth dose curves along the central axis direction of the plaque. To 
study the effect of the eyeball composition, the Monte Carlo simulation of the eye includes 
several (0.05 cm3) voxels that have been selected at the different critical points in the eye as well 
as the tumor apex. With the assumptions and utilization of the approach of Thomson et al44, the 
total dose at the points of interest have been calculated and they are shown in Table 5. The 
relative statistical uncertainty is lower than about 1% with the highest percent in the opposite 
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side of the eye and the lowest percent in the sclera among the prescription points represented in 
this table. The calculated dose at points of interest for seeds in water and plaque in water has 
been compared with that reported by Thomson et al44. The air kerma strength per seed has been 
calculated for 125I model 6711 following the method of the air kerma strength per seed introduced 
by other investigators43-44. Figure 5 presents a comparison between 4 concentrations of GNPs in 
the calculation of dose enhancement factor (DEF) in both phantoms. The dose enhancement 
factor has been plotted in the figure as a function of radial distances from the center of the plaque 
while the plaque is placed next to the tumor in the simulated human eye and the water phantom.  
 
Figure 5: The calculated dose enhancement factors for 50nm GNPs within the tumor with concentrations 
of 7 mg/g, 10 mg/g, 18 mg/g, and 30mg/g in the water and the eye model phantoms. For Monte Carlo 
simulation the tally cells were placed along the central axis of the plaque, starting from the sclera near the 
plaque to the sclera opposite side of the plaque. DEF calculations have been done in the simulated 
human eye using the data shown in Table 2. Fully loaded 16 mm COMS eye plaque has been 
positioned next to the tumor on the equator temporal to the eyeball. A fully simulated human eye 
globe filled with eye material is referred to as (eye) and the water phantom is referred to as 
(water). 
Figure 6 shows the ratio of the central axis depth dose to the dose at the tumor apex for 
16mm COMS eye plaque in water phantom, eye globe and simulated human eye with 
nanoparticles-induced tumor.  These results show that for the same dose to the apex of the tumor 
lower normal tissue doses (distances > 0.5 cm which is the tumor apex) are achieved for larger 
concentration of the nanoparticles.  
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Figure 6: The ratio of the full loaded 16mm COMS eye plaque’s depth doses to the dose at the tumor 
apex in the water phantom, simulated human eye, and simulated eye in which 4 concentrations of GNPs 
are defined inside the tumor. 
 
IV. Discussion 
 
In radiation therapy, the required radiation dose for treatment is chosen based on the type 
of tumor and the rate of its progress. Determination of the required dose for the treatment of a 
specific tumor or the control of the tumor growth can be directly related to the treatment time for 
a given technique. For treatment of ocular melanoma, the prescribed dose is normally to the 
tumor apex. The height of the tumor apex may vary from patient to patient and thus the treatment 
time will vary, to deliver prescribed dose. These changes may affect the dose values to the 
normal tissues in the eye such as sclera, optical nerve, and lens.  Table 5 show that defining the 
nanoparticles in the tumor area lead to the dose increase inside the tumor with no significant 
changes in the absorbed dose by other parts of the eye in both phantom types. The calculated 
doses to the tumor apex in the presence of GNPs inside the tumor with the concentrations of 7 
mg/g, 10 mg/g, 18 mg/g, and 30 mg/g, was found to be increased by a factor of about 1.9, 2.2, 
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3.2 and 4.6, respectively, in the eye model and about 1.9, 2.3, 3.3 and 4.8 orders of magnitude, 
respectively, in the water phantom. 
Despite the similarity of the dose enhancement to the tumor apex for the two phantom 
types, the results shown in Table 5 show that the composition of the eye materials influences the 
calculated dose in the choroidal melanoma. This effect is visible in the absence of GNPs, 
indicating that the dose to the points of interest in the eye phantom differs from that of water 
phantom. The dose to the center of lens and optic disk in the eye is lower than the dose 
calculated in these points in water. On the contrary, the dose to the sclera, apex and the opposite 
side in the eye are more than that of the water phantom. The dose increase in the sclera is about 
28% and the dose reduction in the lens is about 11.6%.  
The differences between the results of dosimetry in the eye model and water phantom are 
more prominent when the GNPs are defined in the tumor. For example, in the presence of 
18mg/g GNPs there is an increase of 20% in the eye model and 4% in the water phantom in the 
dose absorbed to sclera relative to that of the eye and water phantom with no nanoparticles 
present. These differences are mainly due to the impact of the elemental compositions of the two 
phantom types in the photoelectric interaction of the low energy photons from 125I brachytherapy 
sources. Furthermore, with the presence of the plaque relative to the absence of the plaque, our 
results indicate that the dose to the point located opposite to the plaque, has an increase of 
approximately 10% in the water phantom while decreasing by about 7% in the eye phantom.  
This effect also can be attributed to the photoelectric interactions for the low energy photon and 
chemical elements of the two phantom types.   
In table 5, a comparison of the effect of the plaque for multiple seed simulation has been 
shown too. The data shows that the presence of the plaque around the seeds causes a decrease in 
the dose to all points of interest. For instance, the dose to the sclera and tumor apex in the water 
phantom, in the presence of the plaque is about 14% less than that of the absence of the plaque, 
but with the same arrangement. This amount is increased as the distance from the plaque is 
increased. The dose reduction is a consequence of the elemental composition of the plaque 
backing gold alloy and the Silastic seed-career. The high atomic number of the gold causes 
enhanced photoelectric absorption and results in a dose reduction. Table 5 shows that, in the 
presence of the plaque the dose to sclera is approximately 28% larger in eye phantom than that of 
water phantom.  The differences of the aforementioned increase of the dose values are due to the 
differences of the chemical compositions of the phantom material and presence of the plaque.  
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Regarding the results of Table 5 and considering the relative statistical uncertainty lower 
than about 1% in all calculations, the discrepancies between water and eye phantom are 
considerable in all parts of the eye. However, considering systematic uncertainties in eye plaque 
therapy, the discrepancies in some parts such as center of eye and Macula may be in the range of 
uncertainties, and therefore they may not be reliable. 
As can be seen from the Figure 5, the tumor dose enhancement is greater for higher 
concentration of GNPs in both water and the eye phantoms. However, the notable result is that a 
given concentrations of GNPs, the DEF value in the water phantom is larger than that in the eye 
phantom. Moreover, as shown in this figure, the difference between the eye and the water 
phantom increases with increasing nanoparticle concentration. Since the photoelectric cross-
section depends on the atomic number of the material and photon beam energy, the use of the 125I 
as a low energy photon source and GNP as a high Z material will increase the probability of the 
photoelectric interaction inside the tumor. Therefore, as shown in Figure 6, keeping a fixed 
prescribed dose delivery to the apex of the tumor will lead to a lower absorbed dose to the 
normal tissue of the eye.  This reduction is increased by increasing the concentration of the 
GNPs inside the tumor.  
 
V. Conclusion 
In this study, a Monte Carlo simulation model of human eye was built, considering its 
composition closer to reality, and a water phantom to investigate the effects of the GNPs on 
radiation dose enhancement in ophthalmic brachytherapy dosimetry. The results show that a 
significant tumor dose enhancement could be achieved, using GNPs inside the tumor during the 
irradiation by low energy source. With a certain diameter of GNPs, the results of the dose 
calculation show a higher dose enhancement for the greater concentration of GNPs. 
The presence of GNPs inside the tumor made no significant changes in the radiation 
absorbing sensitivity of other normal tissue of the eye. Therefore, for the same delivery of the 
dose to the tumor apex, one may be able to deliver a smaller dose to the normal tissues in the eye 
(Figure 6). Furthermore, comparing the dosimetry calculations in the presence of GNPs between 
the water phantom and the eye model shows the importance of a more accurate definition of the 
eye material in ophthalmic brachytherapy. 
The results of the Monte Carlo study in this investigation show that the presence of GNPs 
inside the tumor could play an important role in dose enhancement. However, the availability of 
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an experimental study (in-vitro or in-vivo) in melanoma could result in a better understanding of 
the effect of GNP in the melanoma dosimetry. A full experimental investigation of the effects of 
the GNPs inside the choroidal melanoma on brachytherapy dosimetry could answer many of the 
questions in this project.  
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                         Table 1: Monte Carlo simulation uncertainties  
 
 
 
 
 
               
                         
                            
                                     
 
Component                                                r = 1 cm                  r = 5 cm               
 
Statisticsa                                                     0.5%                        1.0%                          
Photoionization                                          1.5%                        4.5% 
Cross section     (2.3%)                                                         
Seed geometry                                            2.0%                        2.0%         
Source energy spectrum a                           0.1%                        0.3% 
Quadrature sum                                          2.5%                        5.0%
 
a On the transverse plane of a single source 
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  Table 2: Elemental compositions and densities of different parts of the human eye-ball, water, and dry air used in this simulation.44,47-52 
 
Material Elemental Composition (% by Mass) 
Density 
(g/ 
cm3) 
Material H O C N Na Mg P S Ar Cl K Ca  
Water 11.11901 88.8099 --- --- --- --- --- --- --- --- --- --- 0.9980 
Dry air --- 23.17812 0.012425 75.52673 --- --- --- --- 1.282725 --- --- --- 0.0012 
Lens 9.60 64.60 19.50 5.70 0.10 --- 0.10 0.30 --- 0.10 --- --- 1.07 
Sclera 9.60 74.40 9.90 2.20 --- 0.50 2.20 0.90 --- 0.30 --- --- 1.09 
Vitreous 11.0867 88.052 0.068 --- 0.2647 0.0025 0.002 --- --- 0.502 0.0171 0.005 1.00 
Aqoues 
humor 
11.085 88.06 0.056 0.00001 0.348 0.0025 0.0018 0.00001 --- 0.432 0.00798 0.0067 1.01 
Optic 
nerve 
10.70 76.70 9.50 1.80 0.20 --- 0.30 0.20 --- 0.30 0.30 --- 1.039 
Skull 
bone 
5.00 43.50 21.20 4.00 0.10 0.20 8.10 0.30 --- --- --- 17.60 1.61 
Tumor 10.8 83.2 4.10 1.10 --- 0.30 --- 0.10 --- 0.40 --- --- 1.03 
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Table 3: A comparison between the simulated radial dose function, g(r ), of the oncoseed 6711 
source in this project with the published data by other investigators. 
Distance from source 
(cm) 
Radial Dose Function, g(r ) 
This work Taylor et al63 TG-4354 
0.05 1.115 1.139 ---- 
0.06 1.050 1.094 ---- 
0.07 1.068 1.08 ---- 
0.08 1.069 1.077 ---- 
0.09 1.071 1.078 ---- 
0.10 1.050 1.08 1.055 
0.15 1.064 1.089 1.078 
0.20 1.066 1.096 ---- 
0.25 1.062 1.096 1.082 
0.30 1.059 1.093 ---- 
0.40 1.050 1.086 ---- 
0.50 1.075 1.075 1.071 
0.60 1.060 1.062 ---- 
0.70 1.040 1.048 ---- 
0.75 1.040 1.042 1.042 
 0.80  1.030 1.035 ---- 
0.90 1.012 1.018 ---- 
1.0 0.995 0.998 1 
1.5 0.900 0.909 0.908 
2.0 0.800 0.813 0.814 
2.5 0.710 0.721 ---- 
3.0 0.615 0.633 0.632 
3.5 0.550 0.557 ---- 
4.0 0.472 0.484 0.496 
4.5 0.406 0.419 ---- 
5.0 0.361 0.361 0.364 
5.5 0.310 0.313 ---- 
6.0 0.267 0.269 0.270 
6.5 0.230 0.231 ---- 
7.0 0.199 0.198 0.199 
7.5 0.172 0.171 ---- 
8.0 0.143 0.146 0.148 
8.5 0.123 0.125 ---- 
9.0 0.104 0.107 0.109 
9.5 0.092 0.0914 ---- 
10.0 0.0762 0.0775 0.0803 
 5 
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Table 4: A comparison of the dose rate constant, Ʌ (cGyU-1h-1), of 125I brachytherapy source in 
water, simulated in this project with the published data. 10 
 
R. Taylor, D. 
Rogers63 
M. J. 
Rivard et 
al54 
This work 
Dose rate 
constant 
0.942 0.965 0.923±0.011 
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Table 5:  A comparison of the integrated dose (Gy) at different points of interests in an eye-ball, implanted with a 16 mm eye plaque 
located next to the tumor on the equator temporal to the eyeball. Columns labeled “P.W” and “S.W” compares the dose for 13 125I seeds 
in water phantom with and without the presence of the plaque, respectively. “Eye“ refers to simulated human eye using the data of table 2 
and “water“ refers to the simulated human eye in which all parts of the eye were assumed to be made of water. “Plaque in eye” refers to 15 
the 13 125I seeds with plaque present in human eye phantom.  “7 mg/g, 10 mg/g, 18 mg/g, and 30 mg/g” refer to the concentration of 
GNPs inside the tumor in both phantom types. The relative statistical uncertainty is lower than 1%. 
location 
Thomson 
et al44 
(S.W) 
 
This 
work 
(S.W)  
 
Thomson 
et al44 
(P.W) 
 
This 
work 
(P.W) 
Plque 
in eye 
7mg/g 
(water) 
7mg/g 
(eye) 
10mg/g 
(water) 
10mg/g 
(eye) 
18mg/g 
(water) 
18mg/g 
(eye) 
30mg/g 
(water) 
30mg/g 
(eye) 
Sclera 262.1 261.53 222.7 223.54 285.93 267.73 298.92 267.73 298.92 270.33 298.92 270.33 298.92 
Apex 85.00 85.00 74.40 73.66 76.50 141.38 142.8 168.58 170.29 244.80 245.08 355.0 354.16 
Center 
of  eye 
27.92 27.63 23.68 22.66 22.49 23.80 23.74 23.82 23.77 23.82 23.77 23.80 23.80 
Opposite 
side  
6.83 6.80 5.453 5.16 6.53 5.72 6.09 5.72 6.01 5.72 6.01 5.75 6.01 
Optic 
disk  
11.35 10.39 8.947 8.11 7.80 8.26 8.11 8.24 8.08 8.24 8.08 8.26 8.05 
Lens 21.75 21.45 17.53 17.30 15.30 18.98 15.49 19.09 15.32 19.06 15.32 19.01 15.28 
Macula 16.45 15.75 12.80 11.46 11.62 12.55 12.40 12.53 12.40 12.53 12.40 12.63 12.40 
 
